



**ESO - Educational Cancer Convention Lugano**  
**What's New and What's True in Genito-urinary Oncology?**  
12-14 May 2011, Lugano, Switzerland

Chairs: Dominik Berthold, CH and Bertrand Tombal, BE

An ESMO Supported meeting held under the auspices of the European School of Urology

**Aims, objectives and teaching format of the Educational Cancer Convention Lugano**

The 2011 edition was devoted to genito-urinary oncology with a programme developed with special attention the multidisciplinary care of patients with prostate, bladder, renal and testicular cancer. The programme was equally interesting for urologists, radiation and medical oncologists as well as clinicians in training in those specialties. The programme included state of the art lectures, controversies and gave ample time for discussion of abstracts and clinical cases provided by the participants.

**Key note lecture** dealt on: New developments in the systemic treatment of advanced prostate cancer and was delivered by Dr Ian Tannock.

Several participants gave case presentations or research projects as **oral or poster presentations** and discussed these with the Chairs.

**Controversies** were discussed among faculty and participants and focused particularly to the treatment options of localised and locally advanced prostate cancer.

Several lectures (kidney cancer session and keynote lecture) were transmitted live within the **e-eso online educational program** and are available for 6 months for free ([www.e-eso.net](http://www.e-eso.net)). Most of the slides used by the presenters are available through [www.eso.net](http://www.eso.net).

**Participants' profile**

- Age between 30 and 50 years
- In speciality training or specialist in radiation oncology, medical oncology or urology
- Admission by registration

The attendance by 60 participants was somewhat below expectations considering the high quality faculty. However, lectures transmitted over the internet are frequently watched, highlighting the potential for online education.

**Sponsorship**

ECCLU 2011 offered benefits to the sustaining members of the School (within the Sharing Progress in Cancer Care programme). SPCC sponsors are Amgen, Eisai, Eli Lilly, GSK, Merck Serono, Genomic Health, Novartis Oncology and Sanofi-Aventis. Only Novartis Oncology participated with a sponsored-lecture.

### **About ESO**

The European School of Oncology is an independent organisation. It recognises that the industrial partners are crucial for the delivery of best cancer care and fosters the continuation of the dialogue and identification of synergies. It restrains, however, the influence of marketing and strives to maintain its independence from the sponsors with whom it interacts with a neutral approach. Since its inauguration in 1982, ESO has been promoting cancer education in Europe and abroad.

The original idea of the school is to fight against cancer in optimising training and updating competence of physicians and health care workers dealing with cancer patients in providing them with a comprehensive understanding of oncology - covering all aspects from epidemiology, screening, primary and secondary prevention, molecular-biology, diagnostic procedures, interdisciplinary treatment modalities, rehabilitation, palliative care, to psycho-oncological skills and promoting the importance of controlled randomised trials in clinical oncology. ESO's mission is reflected in its motto "Learning to Care", which stresses the concept of studying and learning and also of caring for the patient in a global sense. By improving the skills of all health professionals dealing with cancer patients, ESO shortens the length of time needed to transfer knowledge from advanced research centres to daily practice, combining advanced technology with humanism in care.

### **ECCLU 2011 Abstract book**

The abstract book containing abstracts provided by the invited speakers and those submitted by the participants and accepted for oral or poster sessions was published as supplement to Critical Reviews in Hematology/Oncology.

### **Summary**

Participants appreciated the high level of this educational event. The evaluation of the participants opinion (questionnaire focussing on programme objectives, programme organisation, course organisation, facilities, and faculty) indicated that the convention met the needs of the participants on most of the items and highlighted the necessity of such an event.

Dominik Berthold, MD  
Chair ECCLU 2011

## ECCLU 2011 Programme

Thursday, 12 May

10.45	Welcome and presentation of the Prostate Units concept	Dominik Berthold and Alberto Costa
-------	--	------------------------------------

11.00	<b>Epidemiology in Europe</b>	Cristina Bosetti, IT
-------	-------------------------------	----------------------

11.15-12.30	<b>Localised invasive bladder cancer</b>	Alex Bex, NL
11.15	Neo-adjuvant chemotherapy	Joachim Bellmunt, ES
11.40	Surgery	George Thalmann, CH
12.05	Radiotherapy	Nicholas James, UK

12.30-13.00	<b>Palliative chemotherapy</b>	
	First-line, second-line, platinum-unfit	Maria De Santis, AT

13.00-14.00 Lunch and poster session

14.00-14.45	<b>Oral abstract presentations</b>	Chair: Ian Tannock, CA
14.00	Ex-vivo ultrasound control of resection margins during partial nephrectomy (Abstract 25)	Yannick Cerantola, CH
14.10	Reasonability of lymph dissection in localized types of renal cell carcinoma (Abstract 26)	Nodir Rahimov, UZ
14.20	Quality of life in metastatic renal cell carcinoma patients with ECOG PS >2 receiving targeted therapy (Abstract 27)	Ilya Tsimafeyeu, RU
14:30-14:40	Choosing the extent of the lymph node dissection in surgical treatment of the bladder cancer with regional metastasis (Abstract 28)	Elena Kolesnikova, UZ

14.45-15.15	Mechanisms of action in modern RCC treatment (Lecture sponsored by Novartis Oncology)	Christian Rothermundt, CH
-------------	---	---------------------------

15.15-15.45 Coffee break

15.45-18.15	<b>Kidney cancer</b> (webcast at <a href="http://www.e-eso.net">www.e-eso.net</a> )	Chair: George Thalmann, CH
15.45	First and further lines in mRCC	Brian I. Rini, US
16.45	Adjuvant and neo-adjuvant treatment	Alex Bex, NL
17.15	Non-clear cell histology	Joachim Bellmunt, ES
17.45	Surgery (including Nephron-sparing surgery)	Hendrik Van Poppel, BE

18.15-19.00	Keynote lecture (webcast at <a href="http://www.e-eso.net">www.e-eso.net</a> )	
	<b>New developments in the systemic treatment of advanced prostate cancer</b>	Ian Tannock, CA

19.00 Welcome cocktail

### Friday, 13 May

8.30-10.30	<b>Prostate cancer: From biology to life expectancy</b>	Chair: Chris Parker, UK
8.30	Biology	Zoran Culig, AT
9.30	Screening and active surveillance	Bertrand Tombal, BE

10.30-11.00 Coffee break

11.00-12.20	<b>Prostate cancer: All the truth about local treatment options T1-T2</b>	Chair: Bertrand Tombal, BE
11.00	> Radiotherapy	Anders Widmark, SE
11.20	> Surgery	Vincenzo Ficarra, IT
11.40	> Brachytherapy	Jan J. Battermann, NL
12.00	> High-intensity focused ultrasound and cryotherapy	François J. Murat, FR

12.20-13.00	<b>Oral abstract presentations</b>	Chair: Dominik Berthold, CH
12.20	12:20 On the role of magnetic resonance imaging with Endorectal Coil (ER-MRI) in changing the stage (and treatment approach) in patients with early prostate cancer undergoing primary radiation (Abstract 29)	Mario Romano, IT
12.30	Weight change analysis in advanced castration resistant prostate cancer (CRPC) patients treated with Abiraterone Acetate (AA) single agent and in combination with steroids (Abstract 30)	Diletta Bianchini, UK
12.40	Evaluating the antitumour activity of docetaxel following treatment with abiraterone acetate and steroids: Evidence for cross-resistance (Abstract 31)	Janusz Mezynski, UK
12.50	Current status of prostate cancer in Lagos, Nigeria (Abstract 32)	Olugbenga Adetayo, NG

13.00-14.00 Lunch and poster session

14.00-15.00	Controversy <b>Locally advanced prostate cancer</b>	Moderator: Bertrand Tombal, BE
14.00	Pro surgery:	Hendrik Van Poppel, BE
14.20	Pro radiation:	Chris Parker, UK
14.40	Discussion and conclusions	Bertrand Tombal, BE

15.00-15.30	<b>Locally advanced prostate cancer: Multimodality treatment and new drugs combined with radiotherapy</b>	Stéphane Supiot, FR
-------------	---	---------------------

15.30-16.00 Coffee break

16.00-17.30	<b>Prostate cancer: Locally advanced disease and patient advocacy</b>	Chair: Dominik Berthold, CH
16.00	Europa Uomo: The patients' voice	Vincent Griesser, CH
16.30	Adjuvant versus salvage radiation	Michel Bolla, FR
17.00	Integrating systemic therapy into high-risk disease	Karim Fizazi, FR

17:30-18:30	<b>Prostate cancer: Management of pelvic nodes</b>	Chair: Bertrand Tombal, BE
17.30	Surgical perspective:	Hendrik Van Poppel
18.00	Radiation perspective:	Thomas Wiegel, DE

### Saturday, 14 May

9:30-10:30	<b>Prostate cancer drug development</b>	Karim Fizazi, FR
------------	---	------------------

10:30-11:00	<b>Side-effects of anti-androgen therapy</b>	Bertrand Tombal, BE
-------------	--	---------------------

11:00-11:30 Coffee break

11.30-12.00	<b>Bone targeted agents</b>	Noel Clarke, UK
-------------	-----------------------------	-----------------

12:00-13.30	<b>Testicular cancer</b>	Chair: Noel Clarke, UK
12.00	Options in stage I testicular cancer	Alan Horwich, UK
12.30	Treatment of advanced testicular cancer	Karim Fizazi, FR
13.00	Role of surgery in the management of testis cancer	Noel Clarke, UK

13.30-13:40	<b>Closing remarks</b>	Dominik Berthold, CH
-------------	------------------------	----------------------

## POSTER SESSION

Pure red cell dysplasia in a patient with metastatic cancer prostate (Abstract 33)	Raafat Abdel Malek, EG
Role of immunohistochemical markers in definition of hormone sensation prostate cancer (Abstract 34)	Elena Kolesnikova, UZ
Intermittent hormonal therapy in the treatment of prostate cancer (Abstract 35)	Nodir Rahimov, UZ
Dural metastases from prostatic adenocarcinoma: Case report and review of literature (Abstract 36)	Ahmed Salem, JO
Cytoreductive nephrectomy in advanced or metastasis renal cell carcinoma: In the era of targeted strategies (Abstract 38)	Ch. Toutziaris, GR
Supraclavicular lymphadenopathy as the initial clinical symptom of a rare histological type of renal cancer (Abstract 39)	Ch. Toutziaris, GR
Atypical initial clinical presentation of a prostate cancer with normal PSA (Abstract 40)	Ch. Toutziaris, GR